Clinical Trial

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-16.
Trial Details
NCT Number NCT07188077
Lead Sponsor Ting YANG
Conditions Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma
Enrollment 20 participants
Start Date 2025-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-18